Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.
作者信息
Okon Lauren, Rosenbach Misha, Krathen Michael, Rose Mathew, Propert Kathleen, Okawa Joyce, Werth Victoria
机构信息
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Department of Biostatistics at HUP, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
出版信息
J Am Acad Dermatol. 2014 Mar;70(3):583-4. doi: 10.1016/j.jaad.2013.11.007.
Abstract
摘要
相似文献
1
Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.来那度胺治疗难治性皮肤红斑狼疮：一项52周试验的疗效与安全性
J Am Acad Dermatol. 2014 Mar;70(3):583-4. doi: 10.1016/j.jaad.2013.11.007.
2
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.来那度胺治疗难治性皮肤红斑狼疮的疗效与安全性。
Arthritis Res Ther. 2012 Dec 7;14(6):R265. doi: 10.1186/ar4111.
3
Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.来那度胺治疗皮肤红斑狼疮：梅奥诊所的经验
Int J Dermatol. 2016 Aug;55(8):e431-9. doi: 10.1111/ijd.13226. Epub 2016 Feb 12.
4
Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.来那度胺用于治疗儿童系统性红斑狼疮的难治性皮肤表现。
Lupus. 2017 May;26(6):646-649. doi: 10.1177/0961203316676377. Epub 2016 Nov 12.
5
Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.来那度胺治疗难治性皮肤红斑狼疮：组织学和循环白细胞特征以及全身性狼疮发作的潜在风险。
J Am Acad Dermatol. 2012 Apr;66(4):571-82. doi: 10.1016/j.jaad.2011.01.015. Epub 2011 Aug 6.
6
Efficacy of lenalidomide in refractory lupus pernio.来那度胺治疗难治性狼疮性冻疮的疗效
JAMA Dermatol. 2013 Apr;149(4):493-4. doi: 10.1001/jamadermatol.2013.1313.
7
Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.静脉注射免疫球蛋白与来那度胺联合治疗硬肿病。
J Am Acad Dermatol. 2013 Aug;69(2):319-20. doi: 10.1016/j.jaad.2013.01.028.
8
Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.来那度胺治疗难治性慢性和亚急性皮肤型红斑狼疮：16例患者。
J Am Acad Dermatol. 2016 Jun;74(6):1248-51. doi: 10.1016/j.jaad.2016.01.054.
9
Cutaneous lupus mucinosis successfully treated with systemic corticosteroid and systemic tacrolimus combination therapy.
J Am Acad Dermatol. 2013 Oct;69(4):e200-2. doi: 10.1016/j.jaad.2013.04.057.
10
Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab.利妥昔单抗成功治疗难治性亚急性皮肤型红斑狼疮。
Australas J Dermatol. 2009 Aug;50(3):202-6. doi: 10.1111/j.1440-0960.2009.00539.x.
引用本文的文献
1
Immunotargets and Therapy for Systemic Lupus Erythematosus.系统性红斑狼疮的免疫靶点与治疗
Immunotargets Ther. 2025 Jun 24;14:605-629. doi: 10.2147/ITT.S485650. eCollection 2025.
2
An update on the management of refractory cutaneous lupus erythematosus.难治性皮肤红斑狼疮的治疗进展
Front Med (Lausanne). 2022 Sep 23;9:941003. doi: 10.3389/fmed.2022.941003. eCollection 2022.
3
Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs.基于数据驱动的患者分层的系统性红斑狼疮的分子分类学：分子内表型和聚类定制药物。
Front Immunol. 2022 May 9;13:860726. doi: 10.3389/fimmu.2022.860726. eCollection 2022.
4
Thalidomide and discoid lupus erythematosus: case series and review of literature.沙利度胺与盘状红斑狼疮：病例系列及文献综述
Drugs Context. 2022 Mar 16;11. doi: 10.7573/dic.2021-9-8. eCollection 2022.
5
Recent Insight on the Management of Lupus Erythematosus Alopecia.红斑狼疮性脱发管理的最新见解
Clin Cosmet Investig Dermatol. 2021 Mar 30;14:333-347. doi: 10.2147/CCID.S269288. eCollection 2021.
6
Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.靶向转录因子 Ikaros 和 Aiolos 对系统性红斑狼疮中 B 细胞激活和分化的影响。
Lupus Sci Med. 2021 Mar;8(1). doi: 10.1136/lupus-2020-000445.
7
Interventions for cutaneous disease in systemic lupus erythematosus.治疗系统性红斑狼疮皮肤病变的干预措施。
Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2.
8
Candidate drug replacements for quinacrine in cutaneous lupus erythematosus.治疗盘状红斑狼疮的候选药物奎那克林替代物。
Lupus Sci Med. 2020 Oct;7(1). doi: 10.1136/lupus-2020-000430.
9
Cutaneous Lupus Erythematosus: Progress and Challenges.皮肤红斑狼疮：进展与挑战。
Curr Allergy Asthma Rep. 2020 Apr 4;20(5):12. doi: 10.1007/s11882-020-00906-8.
10
Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus.评估红斑狼疮患者临床改善的稳健性测量方法。
Lupus Sci Med. 2020 Jan 27;7(1):e000364. doi: 10.1136/lupus-2019-000364. eCollection 2020.
本文引用的文献
1
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.来那度胺治疗难治性皮肤红斑狼疮的疗效与安全性。
Arthritis Res Ther. 2012 Dec 7;14(6):R265. doi: 10.1186/ar4111.
2
Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.来那度胺治疗难治性皮肤红斑狼疮：组织学和循环白细胞特征以及全身性狼疮发作的潜在风险。
J Am Acad Dermatol. 2012 Apr;66(4):571-82. doi: 10.1016/j.jaad.2011.01.015. Epub 2011 Aug 6.
3
Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients.基于网络的红斑狼疮相关皮肤病变协作数据库的横断面分析：114例患者的前瞻性入组。
Arch Dermatol. 2009 Mar;145(3):255-60. doi: 10.1001/archdermatol.2008.594.
4
Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus.低剂量沙利度胺治疗狼疮性红斑难治性皮肤病变
Arch Dermatol. 2003 Jan;139(1):50-4. doi: 10.1001/archderm.139.1.50.
5
Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients.沙利度胺所致神经病变的发病率及危险因素：一项针对135例皮肤科患者的前瞻性研究
J Invest Dermatol. 2002 Nov;119(5):1020-6. doi: 10.1046/j.1523-1747.2002.19502.x.
Zotero 插件